Lexicon Pharmaceuticals, Inc. Earnings Recaps
Q3 2025
Nov 6, 2025
Lexicon Pharmaceuticals reported strong progress in advancing its R&D pipeline during Q3 2025, with significant milestones reached across key therapeutic programs, despite ongoing challenges in the regulatory landscape.
Key takeaways
- Achieved Phase III readiness for pilavapadin, targeting diabetic peripheral neuropathic pain, and ongoing discussions with the FDA for next steps.
- Completed IND-enabling studies for LX9851, entering a partnership with Novo Nordisk that may yield up to $30 million in milestone payments.
- Active enrollment in the Phase III SONATA study for sotagliflozin, addressing both obstructive and non-obstructive hypertrophic cardiomyopathy subtypes.
- Implemented an innovative virtual sales system aimed at transforming INPEFA into a profitable revenue stream by 2026.
- Engaged in proactive discussions with the FDA regarding Zynquista, providing additional supporting data to address previous regulatory concerns.